Brainstorm Cell Therapeutics Inc. filed a current report on November 20, 2026, disclosing that a U.S. federal court entered a Preliminary Approval Order on November 10, 2026, for a proposed settlement of a putative stockholder derivative action against the company.

Key Highlights

  • Court order dated November 10, 2026: The United States District Court for the Southern District of New York entered the Preliminary Approval Order for the proposed derivative settlement.
  • Case caption: The underlying action is captioned In re Brainstorm Cell Therapeutics, Inc. Derivative Litigation, No. 1:24-cv-01095-DEH.
  • Disclosure method required: The Preliminary Approval Order and Stipulation of Settlement require the company to notify stockholders via an regulatory filing or other appropriate filing.
  • Exhibits attached: The Notice of Pendency and Proposed Settlement (Exhibit 99.1) and the Stipulation and Agreement of Settlement (Exhibit 99.2) were attached to the filing.
  • Signed by CEO: The report was signed by Chaim Lebovits, President and Chief Executive Officer, on November 20, 2026.

Court Grants Preliminary Approval of Derivative Litigation Settlement

According to the filing, the United States District Court for the Southern District of New York entered a Preliminary Approval Order on November 10, 2026, preliminarily approving the proposed settlement of a putative stockholder derivative action. Brainstorm Cell Therapeutics Inc., a Delaware-incorporated biopharmaceutical company headquartered at 1325 Avenue of Americas, 28th Floor, New York, NY 10019, disclosed the settlement to stockholders in accordance with that court order.

The filing states that the Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters and the Stipulation and Agreement of Settlement are each attached as exhibits, and that both documents are also accessible through a link on the "Investors and Media" page of the company's website. The company disclosed that "the Preliminary Approval Order and Stipulation of Settlement require the Company to provide this information to its stockholders on Form 8-K or other appropriate regulatory filing."

The filing further notes, under Item 7.01 Regulation FD Disclosure, that the information provided "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," and is not incorporated by reference into other filings unless expressly specified. The securities registered pursuant to Section 12(b) of the Act are listed as none in the filing's registered-securities table.

What Was Disclosed

Brainstorm Cell Therapeutics Inc. reported that a federal court preliminarily approved a proposed stockholder derivative settlement on November 10, 2026, and attached both the settlement notice and the Stipulation and Agreement of Settlement as required by the court's order.